Table 1.
Patient and disease characteristics at first rrHL.
| No ASCT intended (N = 80) | ASCT intended (N = 329) | Total (N = 409) | |
|---|---|---|---|
| Sex | |||
| Female | 33 (41%) | 114 (35%) | 147 (36%) |
| Male | 47 (59%) | 215 (65%) | 262 (64%) |
| Age at rrHL | |||
| Mean (SD) | 48.1 (16.4) | 36.3 (11.8) | 38.6 (13.7) |
| Median | 49.8 | 34.8 | 37.4 |
| Range | (18.9-76.8) | (18.4-66.3) | (18.4-76.8) |
| Age > 60 years at rrHL | |||
| No | 58 (73%) | 323 (98%) | 381 (93%) |
| Yes | 22 (28%) | 6 (2%) | 28 (7%) |
| Clinical stage at 1st diagnosis | |||
| missing | 0 (0%) | 3 (1%) | 3 (1%) |
| I | 16 (20%) | 10 (3%) | 26 (6%) |
| II | 36 (45%) | 167 (51%) | 203 (50%) |
| III | 16 (20%) | 65 (20%) | 81 (20%) |
| IV | 12 (15%) | 84 (26%) | 96 (23%) |
| B-symptoms at 1st diagnosis | |||
| Missing | 0 (0%) | 4 (1%) | 4 (1%) |
| No | 61 (76%) | 153 (47%) | 214 (52%) |
| Yes | 19 (24%) | 172 (52%) | 191 (47%) |
| Time to rrHL | |||
| Missing | 1 | 2 | 3 |
| ≤3 months | 6 (8%) | 68 (21%) | 74 (18%) |
| 3–12 months | 20 (25%) | 104 (32%) | 124 (31%) |
| >12 months | 53 (67%) | 155 (47%) | 208 (51%) |
| Clinical stage at rrHL | |||
| Missing | 0 | 3 | 3 |
| I | 25 (31%) | 43 (13%) | 68 (17%) |
| II | 26 (33%) | 101 (31%) | 127 (31%) |
| III | 15 (19%) | 75 (23%) | 90 (22%) |
| IV | 14 (18%) | 107 (33%) | 121 (30%) |
| B-Symptoms at rrHL | |||
| Missing | 34 | 100 | 134 |
| No | 27 (59%) | 159 (69%) | 186 (68%) |
| Yes | 19 (41%) | 70 (31%) | 89 (32%) |
| Bulk ≥ 5 cm at rrHL | |||
| Missing | 38 | 153 | 191 |
| No | 26 (62%) | 103 (59%) | 129 (59%) |
| Yes | 16 (38%) | 73 (41%) | 89 (41%) |
| EN-disease at rrHL | |||
| Missing | 32 | 114 | 146 |
| No | 34 (71%) | 153 (71%) | 187 (71%) |
| Yes | 14 (29%) | 62 (29%) | 76 (29%) |
| ECOG at rrHL | |||
| Missing | 50 | 149 | 199 |
| 0 | 24 (80%) | 138 (77%) | 162 (77%) |
| 1 | 1 (3%) | 24 (13%) | 25 (12%) |
| 2 | 5 (17%) | 17 (9%) | 22 (10%) |
| 3 | 0 (0%) | 1 (1%) | 1 (0%) |
ASCT high-dose chemotherapy and autologous stem-cell transplantation, rrHL relapsed or refractory classical Hodgkin lymphoma, EN extranodal disease, SD standard deviation.